Cholesterol inclusion in liposomes affects induction of antigen-specific IgG and IgE antibody production in mice by a surface-linked liposomal antigen.
In the previous study, we investigated the induction of ovalbumin (OVA)-specific antibody production in mice by OVA-liposome conjugates made using four different lipid components, including unsaturated carrier lipid and three different saturated carrier lipids. All of the OVA-liposome conjugates tested induced IgE-selective unresponsiveness. The highest titer of anti-OVA IgG was observed in mice immunized with OVA-liposomes made using liposomes with the highest membrane fluidity, suggesting that the membrane fluidity of liposomes affects their adjuvant effect. In this study, liposomes with five different cholesterol inclusions, ranging from 0% to 43% of the total lipid, were made, and the induction of OVA-specific antibody production by OVA-liposome conjugates was compared among these liposome preparations. In contrast to the results in the previous study, liposomes that contained no cholesterol and possessed the lowest membrane fluidity demonstrated the highest adjuvant effect for the induction of IgG antibody production. In addition, when the liposomes with four different lipid compositions were used, OVA-liposome conjugates made using liposomes that did not contain cholesterol induced significantly higher levels of anti-OVA IgG antibody production than did those made using liposomes that contained cholesterol and, further, induced significant production of anti-OVA IgE. These results suggest that cholesterol inclusion in liposomes affects both adjuvanticity for IgG production and regulatory effects on IgE synthesis by the surface-coupled antigen of liposomes.
Nakano
Yoshio
Y
DDS Development Division, NOF Corporation, Tokyo, Japan.
Mori
Masahito
M
Yamamura
Hiroyuki
H
Naito
Seishiro
S
Kato
Hiroshi
H
Taneichi
Maiko
M
Tanaka
Yuriko
Y
Komuro
Katsutoshi
K
Uchida
Tetsuya
T
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects* / Q000276:immunology; D002784:Cholesterol / Q000494:pharmacology*; D004306:Dose-Response Relationship, Immunologic; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry; D005260:Female; D007073:Immunoglobulin E / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology; D008081:Liposomes / Q000008:administration & dosage* / Q000737:chemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology*
D000276:Adjuvants, Immunologic; D004337:Drug Carriers; D007074:Immunoglobulin G; D008081:Liposomes; D007073:Immunoglobulin E; D010047:Ovalbumin; D002784:Cholesterol